10-Q: Biogen Reports Mixed Q2 2025 Results Amidst Strategic Pipeline Investments and Declining MS Sales

Biogen's second quarter 2025 saw a 7.3% increase in total revenue driven by strong Alzheimer's collaboration and contract manufacturing, despite a 1.1% decline in net product revenue primarily from its Multiple Sclerosis portfolio.

Summary

• Total revenue for the three months ended June 30, 2025, increased by $180.6 million, or 7.3%, to $2,645.5 million compared to $2,464.9 million in the prior year period.
• Diluted earnings per share attributable to Biogen Inc. increased by $0.33, or 8.3%, to $4.33 for the three months ended June 30, 2025, from $4.00 in the prior year period.
• Net product revenue decreased by $20.9 million, or 1.1%, to $1,878.7 million for the three months ended June 30, 2025.
• Multiple Sclerosis (MS) product revenue decreased by $42.6 million, or 3.7%, primarily due to increased competition for TECFIDERA and TYSABRI outside the U.S.
• Rare disease product revenue increased by $8.9 million, or 1.7%, driven by new product launches like SKYCLARYS ($130.3 million) and QALSODY ($20.0 million).
• Alzheimer's collaboration revenue significantly increased to $54.9 million for the three months ended June 30, 2025, up from $11.8 million in the prior year, due to higher LEQEMBI sales volumes.
• Contract manufacturing, royalty, and other revenue increased by $135.6 million, or 124.4%, to $244.6 million, primarily from timing of batch commitments.
• Research and development (R&D) expense decreased by $106.4 million, or 21.1%, due to cost reduction measures and portfolio prioritization, partially offset by higher clinical trial spend on litifilimab and felzartamab.
• Acquired in-process R&D, upfront, and milestone expense increased by $38.1 million, primarily due to a $30.0 million milestone for felzartamab (IgAN) and a $16.0 million upfront payment to City Therapeutics.
• Selling, general, and administrative (SG&A) expense increased by $30.0 million, or 5.4%, due to increased operational spending on sales and marketing for LEQEMBI and SKYCLARYS launches.
• Net cash flow provided by operating activities for the six months ended June 30, 2025, was $420.2 million, a significant decrease from $1,179.0 million in the prior year, mainly due to higher worldwide tax payments and timing of customer/employee payments.
• Issued $1.75 billion in new senior unsecured notes in May 2025 and used the proceeds to redeem $1.75 billion of 4.050% Senior Notes due September 15, 2025, prior to maturity.
• Approximately $2.1 billion remained available under the 2020 Share Repurchase Program as of June 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While core product revenue, particularly in MS, is declining due to competition and operating cash flow saw a significant year-over-year decrease, the company demonstrated strong growth in new product launches (LEQEMBI, SKYCLARYS, QALSODY) and strategic pipeline investments (HI-Bio acquisition, collaborations with Stoke and City Therapeutics, Royalty Pharma funding). Cost reduction efforts are also yielding results. The overall picture is one of a company in transition, successfully pivoting towards new growth drivers, but still managing headwinds in its established portfolio.

Positives

• Total revenue increased by 7.3% for the quarter, driven by strong performance in Alzheimer's collaboration and contract manufacturing.
• Diluted earnings per share increased by 8.3% for the quarter.
• Alzheimer's collaboration revenue from LEQEMBI saw a substantial increase of 365.3% for the quarter, reflecting successful launch and market expansion.
• Rare disease product revenue grew by 1.7% for the quarter, with significant contributions from new launches SKYCLARYS and QALSODY.
• R&D expense decreased by 21.1% for the quarter, indicating successful implementation of cost reduction measures and portfolio prioritization.
• Secured $200.0 million in 2025 and up to $50.0 million in 2026 from Royalty Pharma to co-fund the litifilimab program, reducing R&D expense.
• FDA approved LEQEMBI monthly IV maintenance dosing in January 2025 and accepted the BLA for LEQEMBI subcutaneous autoinjector for weekly maintenance dosing with an August 31, 2025 PDUFA date.
• LEQEMBI received traditional approval in the E.U. in April 2025, and was approved in China (January 2024) and Japan (September 2023).
• CHMP of the EMA adopted a positive opinion recommending marketing authorization for ZURZUVAE for PPD in July 2025.
• Initiated dosing in global Phase 3 PREVAIL study for felzartamab in IgAN and Phase 3 PROMINENT study for felzartamab in PMN in June 2025.
• Initiated dosing in global Phase 3 TRANSCEND study for felzartamab in late AMR in March 2025.
• FDA accepted supplemental NDA and EMA validated application for a higher dose regimen of nusinersen (SPINRAZA) for SMA in January 2025.
• Positive topline results from Phase 1b study of salanersen for SMA, showing slowing of neurodegeneration and improvements in motor function.
• SKYCLARYS received approvals in the U.K. and Brazil in April 2025, and Health Canada in March 2025.
• QALSODY received marketing authorization with conditions from Health Canada for ALS in March 2025.
• FDA granted Fast Track designation to BIIB080 for Alzheimer's disease in April 2025.
• SEC Division of Enforcement, DOJ, and SEC closed investigations into ADUHELM, equity plans, and foreign business operations.

Negatives

• Net product revenue decreased by 1.1% for the quarter and 0.2% for the six months ended June 30, 2025.
• Global MS revenue declined by 3.7% for the quarter and 7.4% for the six months, primarily due to increased generic and biosimilar competition for TECFIDERA and TYSABRI.
• Global TECFIDERA revenue decreased by 23.2% for the quarter and 21.1% for the six months due to generic entrants.
• Global TYSABRI revenue decreased by 1.6% for the quarter and 6.4% for the six months due to biosimilar competition in Europe.
• Biosimilars revenue decreased by 8.3% for the quarter and 8.2% for the six months, mainly due to lower IMRALDI sales volumes and competitive pricing pressures in Europe.
• Net cash flow provided by operating activities decreased significantly by 64.4% for the six months, primarily due to higher worldwide tax payments and timing of other payments.
• Net income attributable to Biogen Inc. decreased by $101.7 million for the six months ended June 30, 2025, compared to the same period in 2024.
• Unrealized losses on cash flow hedges increased significantly, contributing to a negative total other comprehensive income (loss) for the period.
• The IRA's drug pricing controls and Medicare Part D redesign are anticipated to have a modest net unfavorable impact of approximately $50.0 million to $100.0 million on 2025 revenue, concentrated in SKYCLARYS and MS portfolio product revenue.

Risks

• Substantial dependence on revenue from existing products, which face increasing competition from new originator therapies, generics, prodrugs, and biosimilars, leading to potential price reductions and lower sales volumes.
• Uncertainty in the successful commercialization of new products like LEQEMBI and SKYCLARYS due to reimbursement challenges, market acceptance, and competition.
• Product development is expensive and uncertain, with a high risk of failure in clinical trials or regulatory approval, especially for novel approaches like ASO and gene therapy.
• Potential for adverse safety events or restrictions on use and safety warnings for marketed or pipeline products, which could lead to product liability, regulatory scrutiny, market withdrawal, and reputational damage.
• Failure to effectively compete in the biopharmaceutical industry due to competitors with greater resources, more products, or technological advantages.
• Inability to obtain and maintain adequate coverage, pricing, and reimbursement from government and private payors, which are subject to intense political, social, and competitive pressures.
• Risks associated with the successful execution and realization of anticipated benefits from strategic and growth initiatives, including acquisitions (Reata, HI-Bio) and cost-reduction programs (Fit for Growth).
• Potential for delays in implementing cost optimization actions, loss of workforce capabilities, and higher than anticipated separation expenses from the Fit for Growth program.
• Dependence on relationships with collaborators and other third parties for revenue, development, regulatory approval, commercialization, and manufacturing, which are outside of full control and subject to disputes or failures.
• Adverse effects from current and potential future healthcare reforms, including the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA), which may impact drug pricing, reimbursement, and operating costs.
• Uncertainties and complexities in the development, manufacture, and commercialization of biosimilars, including reliance on third parties, competitive challenges, regulatory hurdles, supply chain issues, and intellectual property disputes.
• Inability to obtain and maintain adequate protection for data, intellectual property, and other proprietary rights, leading to potential loss of patent protection, inability to engage in certain activities, or significant damages/royalties.
• Breakdowns, invasions, corruptions, destructions, or breaches of information systems and data, including cloud technologies, which could lead to significant liability, business interruptions, and data exposure.
• Increasing use of AI-based software presents risks such as flawed algorithms, biased data, cybersecurity risks, and potential non-compliance with evolving laws and regulations.
• Manufacturing issues, including reliance on single-source providers, compliance with cGMP, global bulk supply risks, and product loss due to contamination or equipment failure, could increase costs and limit supply.
• Management, personnel, and other organizational changes may disrupt operations and lead to difficulties in retaining or attracting qualified personnel.
• Risks of doing business internationally, including geopolitical tensions (Russia-Ukraine, Middle East), tariffs, supply chain disruptions, foreign currency fluctuations, and differing legal/regulatory requirements.
• Uncertainty regarding the full utilization of new manufacturing facilities (Solothurn, RTP) and the potential for incurring excess capacity charges.
• The illegal distribution and sale of counterfeit or unfit versions of products or stolen products could harm reputation and business.
• Increasing use of social media platforms presents risks of noncompliance with regulations, inappropriate disclosure of sensitive information, and negative or inaccurate public commentary.
• Operating results are subject to significant fluctuations due to timing of charges, foreign currency exchange rates, and other unpredictable factors.
• Investments in properties may not be fully realized, potentially leading to impairment charges or significant costs if properties are vacated.
• Inability to access capital and credit markets on favorable terms, which could increase financing costs.
• Indebtedness and significant contingent liabilities could increase vulnerability to adverse economic conditions and limit financial flexibility.
• Investment portfolio is subject to market, interest, and credit risk that may reduce its value.
• No assurance that share repurchases will occur or at favorable prices, potentially negatively affecting stock price.
• Some collaboration agreements contain change in control provisions that may discourage acquisition attempts.
• Effective tax rate fluctuates, and potential tax obligations may exceed accrued amounts due to changes in tax laws or interpretations.

Future Outlook

The company expects total MS revenue to continue declining in 2025 due to increasing competition from generics and biosimilars. Global SPINRAZA revenue is anticipated to be relatively flat in 2025. Growth in rare disease revenue is expected as SKYCLARYS continues its launch in the U.S., Europe, and other international markets. Full-year contract manufacturing revenue for 2025 is expected to remain relatively flat compared to 2024 due to planned plant maintenance. Core R&D expense is projected to decrease in 2025 due to portfolio prioritization, the Fit for Growth program, and R&D funding from Royalty Pharma. A slight increase in full-year 2025 SG&A expense is expected due to continued spending on LEQEMBI and SKYCLARYS product launches. The IRA's drug pricing controls and Medicare Part D redesign are anticipated to have a modest net unfavorable impact of approximately $50.0 million to $100.0 million on 2025 revenue, concentrated in SKYCLARYS and MS portfolio product revenue. The full extent of the IRA's impacts remains uncertain. The OBBBA's tax changes are not expected to have a material impact on consolidated financial statements in 2025, but its overall impact on the business and pharmaceutical industry is uncertain.

Management Comments

• Management believes the long-term competitive position depends on success in discovering and developing innovative, cost-effective products, efficient manufacturing, and effective launch and marketing in a competitive environment.
• Management expects continued growth through acquisitions and key collaborative relationships and funding arrangements.
• Management believes existing funds, combined with cash from operations and access to additional financing, are sufficient to satisfy operating, working capital, strategic alliance, milestone payment, capital expenditure, and debt service requirements for the foreseeable future.
• Management intends to continue committing significant resources to targeted research and development opportunities while investing in the pipeline where there is significant unmet need and potential for highly differentiated drug candidates.

Industry Context

The biopharmaceutical industry remains intensely competitive, with new originator therapies, generics, prodrugs, and biosimilars continually entering the market, leading to significant pricing pressures. Global healthcare costs are under scrutiny, with legislative actions like the IRA and OBBBA in the U.S. aiming to control drug pricing and modify healthcare funding. This environment necessitates a strong focus on pipeline innovation, cost efficiency, and strategic collaborations to maintain market position and drive growth. The company's shift towards rare diseases and Alzheimer's, alongside biosimilar commercialization, reflects a broader industry trend of diversifying portfolios to offset declines in mature product lines facing patent expirations and increased competition.

Comparison to Industry Standards

• The decline in TECFIDERA and TYSABRI revenue due to generic and biosimilar competition aligns with typical industry patterns where originator products face significant revenue erosion post-patent expiry or biosimilar entry. For example, Humira, another major biologic, has seen substantial biosimilar competition impacting its sales.
• The significant increase in LEQEMBI collaboration revenue reflects a successful early-stage launch in the Alzheimer's market, a high-unmet need area, which is a positive indicator compared to the challenges faced by other Alzheimer's drug candidates in the past.
• The company's cost-saving initiatives (Fit for Growth program) and portfolio prioritization are common strategies adopted by large pharmaceutical companies to optimize operations and reallocate resources towards promising pipeline assets in a competitive landscape, similar to restructuring efforts seen at companies like Pfizer or Novartis.
• The acquisition of HI-Bio and collaborations with Stoke and City Therapeutics for novel therapies (anti-CD38 antibody, ASO, RNAi) demonstrate a strategic focus on specialized immunology, rare diseases, and new modalities, mirroring broader industry trends of M&A and partnerships to replenish pipelines and access innovative technologies.

Management Changes

Corporate Governance

Legal Proceedings

• Three securities actions pending in the District Court, alleging violations of federal securities laws related to statements about ADUHELM, LEQEMBI, TECFIDERA, and VUMERITY, seeking class action status and monetary relief.
• Five derivative actions pending in the District Court, alleging breach of fiduciary duty, waste of corporate assets, and other common law claims related to ADUHELM, LEQEMBI, compliance controls, and 2023 earnings guidance, seeking declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys' fees.
• IMRALDI Patent Litigation: Fresenius Kabi filed a claim for damages and injunctive relief in France alleging infringement of the EP '488 Patent by a formulation of IMRALDI no longer commercialized. The Higher Regional Court of Düsseldorf held that a formulation of IMRALDI infringes the German counterpart of the EP '488 Patent, ordering an injunction and right to seek damages.
• Litigation with Former Convergence Shareholders: Shareholder Representative Services LLC and 24 former shareholders filed a suit in the High Court of Justice of England and Wales seeking $49.9 million plus interest and costs for alleged breaches of contract related to the 2015 acquisition of Convergence. Trial concluded in May 2025, with a final decision pending.
• Humana Patient Assistance Litigation: Humana filed suit alleging damages related to providing MS patients with free medications and charitable contributions to non-profit organizations, alleging breach of contract, fraud, and other state law claims.
• Lender Litigation: A previously disclosed suit filed in 2024 by BioPharma Credit PLC against Biogen and Reata Pharmaceuticals, Inc. was discontinued with prejudice by agreement of the parties in April 2025.
• Antitrust Litigation: Sued by Local No. 1 Health Fund and others in the U.S. District Court for the Northern District of Illinois, alleging violations of federal antitrust laws and various state laws based on contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY. The case was dismissed without prejudice in June 2025, with leave to amend the complaint.
• Italian Competition Authority is investigating Biogen and other companies in relation to the biosimilar product BYOOVIZ.
• TYSABRI Biosimilar Patent Matter: Filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc. and Polpharma Biologics S.A. seeking a declaratory judgment of patent infringement.
• Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents: Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings against Zydus Worldwide DMCC and others. The parties reached a settlement in July 2025, and the court dismissed the case.
• Eisai Matter: Filed a request for arbitration in the International Court of Arbitration of the International Chamber of Commerce seeking adoption of a budget and commercialization plan for the European Territory that allocates commercialization activities equitably between Biogen and Eisai.

Related Party Transactions

• Collaboration agreements with Genentech (Roche Group) for anti-CD20 therapeutic programs (RITUXAN, GAZYVA, LUNSUMIO, OCREVUS, COLUMVI), involving profit-sharing, royalties, and development responsibilities.
• Collaboration agreement with Ionis Pharmaceuticals, Inc. for SMA drug candidates (SPINRAZA, salanersen), involving milestone payments and tiered royalties.
• Collaboration agreement with Eisai Co., Ltd. for LEQEMBI (lecanemab) for Alzheimer's disease, involving equal sharing of costs, profits/losses, and a supply agreement for manufacturing.
• Collaboration agreement with UCB for dapirolizumab pegol for SLE, involving equal sharing of costs, profits/losses, and development responsibilities.
• Global collaboration and license agreement with Sage Therapeutics, Inc. for ZURZUVAE (zuranolone) for PPD, involving equal sharing of development costs and U.S. commercialization profits/losses, and potential tiered royalties outside the U.S.
• Collaboration and license agreement with Denali Therapeutics Inc. for BIIB122 for Parkinson's disease, involving shared development costs and commercialization profits/losses in the U.S. and China, and potential tiered royalties outside these territories.
• Collaboration and license agreement with Stoke Therapeutics, Inc. for zorevunersen for Dravet syndrome, involving an upfront payment, shared external clinical development costs, and potential development/commercial milestone payments and tiered royalties.
• Funding agreement with Royalty Pharma to co-fund development costs for the litifilimab program, involving upfront funding and potential approval-based milestone payments and mid-single digit royalties on net sales.
• In-license commitments under third-party agreements with MorphoSys (acquired with HI-Bio) for felzartamab, involving tiered royalties and potential development, regulatory, and commercial milestone payments.
• Strategic research arrangement with City Therapeutics, Inc. for RNAi therapies, involving an upfront payment, an investment in a convertible note, and potential research, development, and sales-based milestone payments and tiered royalties.
• Commercial agreements with Samsung Bioepis Co., Ltd. for biosimilar products (BENEPALI, IMRALDI, FLIXABI, BYOOVIZ, OPUVIZ), involving pre-specified gross margins, profit/loss sharing, and single-digit royalties.

Stakeholder Impact

• Shareholders: Impacted by fluctuations in revenue and net income, strategic investments in pipeline, share repurchase programs, and ongoing litigation outcomes. The disposal of Sage common stock and the early redemption of senior notes affect capital structure and investment portfolio.
• Employees: Affected by the Fit for Growth cost-saving program, which includes net headcount reductions of approximately 1,400 employees, potentially impacting morale and retention. New corporate headquarters lease aims to integrate teams, potentially improving collaboration.
• Customers/Patients: Benefit from new product launches (LEQEMBI, SKYCLARYS, QALSODY) and pipeline advancements for serious diseases. However, increased competition for existing products and the IRA's drug pricing controls may impact access, pricing, and reimbursement for certain therapies.
• Suppliers/Creditors: Impacted by changes in manufacturing capacity, supply chain disruptions, and the company's debt management activities, including the issuance of new senior notes and repayment of existing debt. Reliance on single-source providers and contract manufacturers poses risks.
• Regulatory Authorities: Engaged with the company through product approvals, clinical trial oversight, and investigations. The closure of SEC/DOJ investigations indicates resolution of certain regulatory matters, while ongoing patent litigation and competition authority investigations continue.

Next Steps

• Advance salanersen to a Phase 3 registrational study for SMA, engaging with regulators.
• Continue to launch SKYCLARYS in the U.S., Europe, and certain rest of world markets.
• Monitor the impact of the IRA's drug pricing controls and Medicare Part D redesign on full-year sales.
• Monitor the evolving global tariff landscape and assess potential impacts on business.
• Monitor the ongoing geopolitical conflicts and assess any potential impacts on business, supply chain, partners, or customers.
• Continue to assess the potential impact of the OBBBA on consolidated financial statements as additional information and guidance become available.
• Continue to work with third-party contract manufacturers for IMRALDI and BENEPALI to address supply constraints and ensure supply continuity following the acquisition of one manufacturer.
• Seek adoption of a budget and commercialization plan for the European Territory for LEQEMBI through arbitration with Eisai.
• Evaluate opportunities to sublease the single-tenant, build-to-suit building in Plano, Texas, acquired with Reata.
• Continue to defend the validity of the EP 2 653 873 patent related to TECFIDERA in opposition proceedings in the European Patent Office and national litigation.
• Engage in legal proceedings to determine the validity, scope, or non-infringement of patent rights claimed by third parties.
• Continue to build and improve information systems and infrastructure, including business continuity plans, to mitigate cybersecurity threats.
• Monitor new or evolving laws and regulations regarding AI-based software and ensure compliance.
• Obtain regulatory approval for the Solothurn facility for the manufacturing of other products beyond LEQEMBI.
• Complete the technology transfer process to enable LEQEMBI manufacturing in the U.S.
• Continue modernizing, automating, and supporting capacity requirements at existing manufacturing facilities in RTP, North Carolina.
• Continue to assess the overall impact of the OBBBA on the business, results of operations, and financial condition, and the pharmaceutical industry as a whole.

Key Dates

Recommendation

Biogen is in a transitional phase, balancing declining revenue from its mature MS portfolio with significant investments in new growth drivers, particularly in Alzheimer's and rare diseases. While the strong performance of LEQEMBI and the promising pipeline developments (felzartamab, salanersen, BIIB080) are positive indicators for future growth, the substantial decrease in operating cash flow, ongoing competitive pressures on key products, and various legal challenges introduce considerable uncertainty. The company's strategic acquisitions and collaborations are positive long-term moves, but their full impact and success are yet to be realized. A 'hold' recommendation reflects this mixed outlook, suggesting investors monitor the execution of new product launches and pipeline progression against the backdrop of continued headwinds in established markets and the broader healthcare regulatory environment.

Keywords

Biopharmaceutical, Neurology, Multiple Sclerosis, Alzheimer's Disease, Rare Disease, Spinal Muscular Atrophy, Friedreich Ataxia, Amyotrophic Lateral Sclerosis, Postpartum Depression, Biosimilars, Drug Development, Clinical Trials, Regulatory Approval, SEC Filing, Financial Results, Revenue, Earnings Per Share, Research and Development, Cost Savings, LEQEMBI, SKYCLARYS, SPINRAZA, QALSODY, ZURZUVAE, TECFIDERA, TYSABRI, HI-Bio, Royalty Pharma, Stoke Therapeutics, City Therapeutics, Intellectual Property, Competition, Healthcare Reform, IRA, OBBBA, Supply Chain, Cybersecurity, Litigation